This product is used in combination with cartegravir injection to treat human immunodeficiency virus type 1 (HIV-1) infection in the following adults: who are receiving a stable antiretroviral regimen and are in a virologically suppressed state (HIV-1 RNA <50 copies/mL), have no past or current evidence of viral resistance to NNRTI and INI drugs, and have not experienced virological treatment failure with previous use of NNRTI and INI drugs.
Let us work together to protect precious health